Eligible patients ( pain intensity 5 [ 11-point numerical rating scale ] on prior analgesics ) were randomized ( 2:1 ) and titrated to their optimal dose of tapentadol PR ( 100-250 mg bid ) or morphine sulfate CR ( 40-100 mg bid ) over 2 weeks .